JP2021513997A5 - - Google Patents

Info

Publication number
JP2021513997A5
JP2021513997A5 JP2020544277A JP2020544277A JP2021513997A5 JP 2021513997 A5 JP2021513997 A5 JP 2021513997A5 JP 2020544277 A JP2020544277 A JP 2020544277A JP 2020544277 A JP2020544277 A JP 2020544277A JP 2021513997 A5 JP2021513997 A5 JP 2021513997A5
Authority
JP
Japan
Prior art keywords
composition according
seq
amino acid
acid sequence
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020544277A
Other languages
English (en)
Japanese (ja)
Other versions
JP7258038B2 (ja
JP7258038B6 (ja
JP2021513997A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/018963 external-priority patent/WO2019165075A1/en
Publication of JP2021513997A publication Critical patent/JP2021513997A/ja
Publication of JP2021513997A5 publication Critical patent/JP2021513997A5/ja
Priority to JP2023060944A priority Critical patent/JP2023089063A/ja
Publication of JP7258038B2 publication Critical patent/JP7258038B2/ja
Application granted granted Critical
Publication of JP7258038B6 publication Critical patent/JP7258038B6/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020544277A 2018-02-21 2019-02-21 B7-h4抗体の投薬計画 Active JP7258038B6 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023060944A JP2023089063A (ja) 2018-02-21 2023-04-04 B7-h4抗体の投薬計画

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862633527P 2018-02-21 2018-02-21
US62/633,527 2018-02-21
US201962802100P 2019-02-06 2019-02-06
US62/802,100 2019-02-06
PCT/US2019/018963 WO2019165075A1 (en) 2018-02-21 2019-02-21 B7-h4 antibody dosing regimens

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023060944A Division JP2023089063A (ja) 2018-02-21 2023-04-04 B7-h4抗体の投薬計画

Publications (4)

Publication Number Publication Date
JP2021513997A JP2021513997A (ja) 2021-06-03
JP2021513997A5 true JP2021513997A5 (cg-RX-API-DMAC7.html) 2022-03-01
JP7258038B2 JP7258038B2 (ja) 2023-04-14
JP7258038B6 JP7258038B6 (ja) 2023-04-25

Family

ID=65686103

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020544277A Active JP7258038B6 (ja) 2018-02-21 2019-02-21 B7-h4抗体の投薬計画
JP2023060944A Pending JP2023089063A (ja) 2018-02-21 2023-04-04 B7-h4抗体の投薬計画

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023060944A Pending JP2023089063A (ja) 2018-02-21 2023-04-04 B7-h4抗体の投薬計画

Country Status (12)

Country Link
US (3) US20210070862A1 (cg-RX-API-DMAC7.html)
EP (1) EP3755719A1 (cg-RX-API-DMAC7.html)
JP (2) JP7258038B6 (cg-RX-API-DMAC7.html)
KR (1) KR102863169B1 (cg-RX-API-DMAC7.html)
CN (1) CN111868089B (cg-RX-API-DMAC7.html)
AU (1) AU2019226009B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020016990A2 (cg-RX-API-DMAC7.html)
IL (1) IL276623A (cg-RX-API-DMAC7.html)
MA (1) MA51902A (cg-RX-API-DMAC7.html)
MX (1) MX2020008730A (cg-RX-API-DMAC7.html)
SG (1) SG11202007820QA (cg-RX-API-DMAC7.html)
WO (1) WO2019165075A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202000387YA (en) 2017-08-25 2020-03-30 Five Prime Therapeutics Inc B7-h4 antibodies and methods of use thereof
WO2019165077A1 (en) * 2018-02-21 2019-08-29 Five Prime Therapeutics, Inc. B7-h4 antibody formulations
KR20200144094A (ko) 2018-03-02 2020-12-28 파이브 프라임 테라퓨틱스, 인크. B7-h4 항체 및 이의 사용 방법
AU2019361923B2 (en) * 2018-10-15 2026-07-09 Five Prime Therapeutics, Inc. Combination therapy for cancer
WO2022147532A1 (en) 2021-01-04 2022-07-07 Mersana Therapeutics, Inc. B7h4-targeted antibody-drug conjugates and methods of use thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
US7029872B2 (en) 2000-06-28 2006-04-18 Glycofi, Inc Methods for producing modified glycoproteins
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
JPWO2002030954A1 (ja) 2000-10-06 2004-02-19 協和醗酵工業株式会社 抗体を精製する方法
CN103333860B (zh) 2000-10-06 2015-07-08 协和发酵麒麟株式会社 产生抗体组合物的细胞
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
CA2923247A1 (en) 2002-03-19 2003-09-25 Stichting Dienst Landbouwkundig Onderzoek Optimizing glycan processing in plants
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
KR101498588B1 (ko) 2003-01-22 2015-03-05 로슈 글리카트 아게 융합 구성체와 Fc 수용체 결합 친화도 및 이펙터 기능이 증가된 항체를 생성하기 위한 이의 용도
EP1888649A2 (en) 2005-05-09 2008-02-20 GlycArt Biotechnology AG Antigen binding molecules having modified fc regions and altered binding to fc receptors
MX2008009220A (es) 2006-01-17 2008-10-10 Biolex Therapeutics Inc Composiciones y metodos para la humanizacion y optimizacion de n-glicanos en plantas.
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
LT2691417T (lt) 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
US9676854B2 (en) * 2011-08-15 2017-06-13 Medimmune, Llc Anti-B7-H4 antibodies and their uses
AU2013361275B2 (en) * 2012-12-19 2016-11-24 Amplimmune, Inc. Anti-human B7-H4 antibodies and their uses
MX374785B (es) 2013-08-01 2025-03-06 Five Prime Therapeutics Inc Anticuerpos anti-fgfr2iiib afucosilados.
CN107299085B (zh) * 2017-05-26 2020-09-29 广东医科大学 分泌抗人b7-h4胞外单克隆抗体杂交瘤细胞株和抗人b7-h4单克隆抗体及其应用
SG11202000387YA (en) 2017-08-25 2020-03-30 Five Prime Therapeutics Inc B7-h4 antibodies and methods of use thereof
WO2019165077A1 (en) 2018-02-21 2019-08-29 Five Prime Therapeutics, Inc. B7-h4 antibody formulations

Similar Documents

Publication Publication Date Title
JP2022513350A5 (cg-RX-API-DMAC7.html)
KR102757960B1 (ko) 간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료
JP2017514461A5 (cg-RX-API-DMAC7.html)
JP2018538274A5 (cg-RX-API-DMAC7.html)
JP2021514379A5 (cg-RX-API-DMAC7.html)
JP2021515568A5 (cg-RX-API-DMAC7.html)
JP2021533726A5 (cg-RX-API-DMAC7.html)
JP2021515565A5 (cg-RX-API-DMAC7.html)
JP2020534250A5 (cg-RX-API-DMAC7.html)
JP2020503273A5 (cg-RX-API-DMAC7.html)
JP2019516394A5 (cg-RX-API-DMAC7.html)
JP2020515247A5 (cg-RX-API-DMAC7.html)
JP2017501167A5 (cg-RX-API-DMAC7.html)
JP2022512750A5 (cg-RX-API-DMAC7.html)
JP2013502913A5 (cg-RX-API-DMAC7.html)
JP2017535257A5 (cg-RX-API-DMAC7.html)
JP2019535250A5 (cg-RX-API-DMAC7.html)
JP2023540526A5 (cg-RX-API-DMAC7.html)
JP2017534577A5 (cg-RX-API-DMAC7.html)
JP2017500028A5 (cg-RX-API-DMAC7.html)
JP2017501157A5 (cg-RX-API-DMAC7.html)
JP2017500057A5 (cg-RX-API-DMAC7.html)
JP2021525806A5 (cg-RX-API-DMAC7.html)
JP2020528936A5 (cg-RX-API-DMAC7.html)
JP2023517794A5 (cg-RX-API-DMAC7.html)